Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Repair Inc.
Angioblast Systems has begun what it says is the first clinical trial with allogeneic stem cells for the treatment of serious heart failure.
Ikaria has obtained a worldwide exclusive licence to BioLineRx’s BL-1040, a potential treatment for preventing cardiac damage following a heart attack, for up to $282.5 million.
Genomics research in Canada has received a Cdn$94 million ($51.5 million) boost from the Ontario government to support continued research in the area.
A cell-based medicine for repairing knee damage has become the first product to be recommended for approval by the European Medicines Agency under the EU's new advanced therapy regulatory framework.
- Drug Delivery